Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Wollenberg A, et al. Among authors: lacour jp. Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30. Br J Dermatol. 2021. PMID: 33000465 Free PMC article. Clinical Trial.
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, Gooderham M, Gebauer K, Tada Y, Lacour JP, Bianchi L, Egeberg A, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Mehta NN. Fernandez AP, et al. Among authors: lacour jp. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1774-1783. doi: 10.1111/jdv.18167. Epub 2022 Jun 25. J Eur Acad Dermatol Venereol. 2022. PMID: 35460287 Free PMC article. Clinical Trial.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Simpson EL, et al. Among authors: lacour jp. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. Br J Dermatol. 2020. PMID: 31995838
Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, Milpied B, Pelvet B, Kasujee I, Gharbi H, Lacour JP. Bérard F, et al. Among authors: lacour jp. Br J Dermatol. 2019 Jan;180(1):56-66. doi: 10.1111/bjd.16904. Epub 2018 Sep 17. Br J Dermatol. 2019. PMID: 29927483 Clinical Trial.
Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study.
Montaudié H, Albert-Sabonnadière C, Acquacalda E, Fontas E, Danré A, Roux C, Ortonne JP, Lacour JP, Euller-Ziegler L, Passeron T. Montaudié H, et al. Among authors: lacour jp. J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1186-91. doi: 10.1111/jdv.12255. Epub 2013 Aug 24. J Eur Acad Dermatol Venereol. 2014. PMID: 23981008
522 results